Get the Stockscreener App
45.43
7.40%
3.13
After Hours:
45.46
0.03
+0.07%
Scholar Rock Holding Corp stock is traded at $45.43, with a volume of 1.69M.
It is up +7.40% in the last 24 hours and down -3.28% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$42.30
Open:
$43.03
24h Volume:
1.69M
Relative Volume:
1.46
Market Cap:
$5.22B
Revenue:
$47.30M
Net Income/Loss:
$-377.94M
P/E Ratio:
-13.26
EPS:
-3.4256
Net Cash Flow:
$-300.64M
1W Performance:
+14.17%
1M Performance:
-3.28%
6M Performance:
+31.72%
1Y Performance:
+36.51%
1-Day Range:
$43.03
$45.64
1-Week Range:
$38.75
$47.87
52-Week Range:
$22.71
$49.82
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
45.43 | 4.86B | 47.30M | -377.94M | -300.64M | -3.4256 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
JPMorgan Chase & Co. Buys 440,401 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
SRRK PE Ratio & Valuation, Is SRRK Overvalued - Intellectia AI
Stocks flashing renewed technical strength: Scholar Rock Holding - MSN
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SRRK Earnings History & Surprises | EPS & Revenue Results | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Scholar Rock Holding Surges 10.6% in Intraday Trade – What’s Behind the Volatility? - Bitget
BMO reiterates Scholar Rock stock rating on rival drug discontinuation By Investing.com - Investing.com South Africa
Truist reiterates Buy on Scholar Rock stock after Roche halts rival drug By Investing.com - Investing.com South Africa
Truist reiterates Buy on Scholar Rock stock after Roche halts rival drug - Investing.com
BMO reiterates Scholar Rock stock rating on rival drug discontinuation - Investing.com
Scholar Rock (SRRK) Shares Surge Following Analyst Note - GuruFocus
Cantor Fitzgerald reiterates Scholar Rock stock rating on rival setback - Investing.com
Cantor Fitzgerald reiterates Scholar Rock stock rating on rival setback By Investing.com - Investing.com Canada
Scholar Rock (NASDAQ:SRRK) Trading Up 7.1%Here's Why - MarketBeat
Scholar Rock (SRRK) Sees Significant Price Increase in Afternoon Trading - GuruFocus
SRRK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
2,461,596 Shares in Scholar Rock Holding Corporation $SRRK Bought by Holocene Advisors LP - MarketBeat
JPMorgan raises Scholar Rock stock price target on drug approval outlook - Investing.com Nigeria
Scholar Rock (NASDAQ:SRRK) Price Target Raised to $50.00 - MarketBeat
SRRK Analyst Update: JP Morgan Raises Price Target to $50.00 | S - GuruFocus
JPMorgan raises Scholar Rock stock price target on drug approval outlook By Investing.com - Investing.com South Africa
HighVista Strategies LLC Purchases 28,343 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Granahan Investment Management LLC Raises Holdings in Scholar Rock Holding Corporation $SRRK - MarketBeat
Eventide Asset Management LLC Has $104.27 Million Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Five new hires at Scholar Rock receive 60,655 shares in inducement grants - Stock Titan
Scholar Rock at Barclays Conference: Strategic Moves in Healthcare By Investing.com - Investing.com Nigeria
Volatility Watch: Is Scholar Rock Holding Corporation stock undervalued right nowNew Guidance & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Scholar Rock at Barclays Conference: Strategic Moves in Healthcare - Investing.com India
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% - AOL.com
Scholar Rock at Leerink Conference: Strategic Path Amid FDA Delays By Investing.com - Investing.com Nigeria
Scholar Rock at Leerink Conference: Strategic Path Amid FDA Delays - Investing.com
Scholar Rock Jumps 7% on $550M Funding: Here’s Where the Stock Could Go in 2026 - TIKR.com
Will Scholar Rock’s Rising Losses, Shelf Filing and Apitegromab Push Change Scholar Rock Holding's (SRRK) Narrative - simplywall.st
Q1 EPS Estimates for Scholar Rock Boosted by HC Wainwright - MarketBeat
Can Scholar Rock Holding Corporation maintain sales growthWeekly Profit Summary & Weekly Breakout Watchlists - baoquankhu1.vn
A Look At Scholar Rock Holding (SRRK) Valuation After Wider Losses And New Shelf Registration - simplywall.st
FY2030 EPS Estimates for Scholar Rock Raised by Analyst - MarketBeat
Scholar Rock (SRRK) Q4 2025 Earnings Transcript - AOL.com
Fisher Asset Management LLC Has $19.86 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
SRRK SEC FilingsScholar Rock Holding 10-K, 10-Q, 8-K Forms - Stock Titan
Scholar Rock at TD Cowen Conference: Strategic Vision and Challenges By Investing.com - Investing.com South Africa
Scholar Rock at TD Cowen Conference: Strategic Vision and Challenges - Investing.com Nigeria
Piper Sandler raises Scholar Rock stock price target on SMA launch - Investing.com India
SRRK: Citigroup Raises Price Target to $58, Maintains Buy Rating | SRRK Stock News - GuruFocus
Citigroup Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price - MarketBeat
Scholar Rock Holding (SRRK) Sees Price Target Raised by Truist S - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Piper Sandler Raises Price Target for SRRK to $58.00, Maintains Overweight Rating | SRRK Stock News - GuruFocus
Scholar Rock (NASDAQ:SRRK) Sees Unusually-High Trading Volume Following Earnings Beat - MarketBeat
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):